Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ

$49.33

-$1.16 (2.30%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$49.27$50.93

Open $50.71

52 Week Range

$24.10$56.15

Previous Close $50.49

Market Cap4.68B

Volume635.90K

Avg Volume1.59M

P/E (TTM)-10.98

EPS (TTM)$-4.49

Dividend / YieldN/A

Dividend StreakN/A

Latest News for Crinetics Pharmaceuticals, Inc.

DEC11

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing ...

globenewswire.com•4 days ago

DEC10

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non...

globenewswire.com•5 days ago

DEC6

Capital Fund Management S.A. Makes New $424,000 Investment in Crinetics Pharmaceuticals, Inc. $CRNX

Capital Fund Management S.A. acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the second quarter, according to its most recent filing with the Securities and Exchange Commi...

defenseworld.net•10 days ago

DEC3

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with...

globenewswire.com•12 days ago

DEC3

Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Fisher Asset Management LLC decreased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 4.7% in the second quarter, according to its most recent disclosure with the Securities and Exch...

defenseworld.net•13 days ago

DEC2

Creative Planning Sells 1,445 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Creative Planning lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commiss...

defenseworld.net•14 days ago

NOV27

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year

Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRN...

fool.com•18 days ago

NOV24

Geode Capital Management LLC Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX

Geode Capital Management LLC boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 1.0% in the undefined quarter, according to the company in its most recent 13F filing with the Secur...

defenseworld.net•22 days ago

NOV20

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community...

globenewswire.com•25 days ago

NOV10

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-...

globenewswire.com•35 days ago